|
BRAF-mutant metastatic colorectal cancer: Prognostic and predictive value of primary tumor location—A pooled analysis of the AIO studies FIRE-1, CIOX, XELAVIRI, FIRE-3, and VOLFI. |
|
Annabel Helga Sophie Alig |
Consulting or Advisory Role - MSD |
|
|
Honoraria - Amgen; AstraZeneca; Merck; Pfizer; Pierre Fabre; Roche; Sanofi; SERVIER; Sirtex Medical |
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Merck; MSD; MSD Oncology; Novartis; Pierre Fabre; Roche; Sanofi; Sirtex Medical; TERUMO |
Research Funding - Amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Servier (Inst); Sirtex Medical (Inst) |
Travel, Accommodations, Expenses - Amgen; Bayer; Merck; Roche; SERVIER; Sirtex Medical |
|
|
Honoraria - Amgen; Bayer; LEO Pharma; Lilly; Merck KGaA; MSD; Pierre Fabre; Roche; Sanofi; SERVIER; Taiho Pharmaceutical; Takeda |
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Lilly; Merck KGaA; MSD; Pierre Fabre; Roche; Sanofi; Sanofi; SERVIER; Takeda |
Research Funding - Merck Serono (Inst); Pierre Fabre (Inst); Roche Molecular Diagnostics (Inst) |
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck KGaA; Pierre Fabre; Roche; Sanofi; Sirtex Medical; Takeda |
|
|
Consulting or Advisory Role - Amgen; MSD; SERVIER |
|
|
Honoraria - Lilly; Novartis; Pierre Fabre |
|
|
Consulting or Advisory Role - Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - SERVIER (Inst) |
Travel, Accommodations, Expenses - Amgen; Lilly |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Roche; SERVIER; Taiho Pharmaceutical |
Travel, Accommodations, Expenses - Amgen; Lilly; Pfizer; Roche |
|
|
|
Travel, Accommodations, Expenses - Medac; Roche |
|
|
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; MCI Group; Merck Serono; MSD; Roche |
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD; Pierre Fabre; Roche |
Research Funding - AIO-Studien (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); AstraZeneca (Inst); BioNTech (Inst); Celgene (Inst); ERYTECH Pharma (Inst); Ipsen (Inst); Lilly (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Servier (Inst) |
Travel, Accommodations, Expenses - Roche |
|
|
Honoraria - Amgen; Falk Pharma; Medupdate; Merck; Pfizer |
|
|
Stock and Other Ownership Interests - Aignostics |
Honoraria - Agilent (I); Aignostics; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; Novartis; Roche |
Consulting or Advisory Role - Agilent; Aignostics; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; Novartis; Roche |
Speakers' Bureau - Agilent; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; Novartis; Roche |
Travel, Accommodations, Expenses - Agilent; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; Novartis; Roche |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Biocartis; Novartis |
Speakers' Bureau - Amgen; AstraZeneca; Bayer; Biocartis; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck KGaA; MSD; Novartis; Qiagen; QuiP; Roche Pharma AG; Takeda; Thermo Fisher Scientific |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Biocartis; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck KGaA; MSD; Novartis; Qiagen; QuiP; Roche Pharma AG; Takeda; Thermo Fisher Scientific |
|
|
Honoraria - Grunenthal; Roche |
Consulting or Advisory Role - Elsevier |
Travel, Accommodations, Expenses - Roche |
|
|
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Incyte; Lilly; Merck Serono; Merck Sharp & Dohme; Onkowissen; Pierre Fabre; Sanofi; SERVIER; Taiho Pharmaceutical |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Cor2Ed; Incyte; IQvia; Lilly; Merck Serono; Merck Sharp & Dohme; Onkowissen; Pierre Fabre; Roche; SERVIER |
Research Funding - Amgen (Inst); Servier (Inst) |
Travel, Accommodations, Expenses - Amgen; Merck Serono; SERVIER |